Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
CymaBay Doubles After-Hours On Positive NASH Trial Update
06:20am, Tuesday, 12'th May 2020
Shares in CymaBay Therapeutics (CBAY) exploded over 105% in after-hours trading Monday after the company revealed a positive update for its seladelpar liver disease drug, which has been on clinical ho
CymaBay Therapeutics Inc (CBAY) Q1 2020 Earnings Call Transcript
06:00am, Tuesday, 12'th May 2020
CBAY earnings call for the period ending March 31, 2020.
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2020 Results - Earnings Call Transcript
04:10am, Tuesday, 12'th May 2020
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2020 Earnings Conference Call May 11, 2020 04:30 PM ET Company Participants Dan Menold - Vice President, Finance Suj
Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study
12:00am, Tuesday, 12'th May 2020
Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament...
CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update
08:01pm, Monday, 11'th May 2020
CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updat
CymaBay Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
12:00am, Monday, 11'th May 2020The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11
08:43pm, Monday, 04'th May 2020
NEWARK, Calif., May 04, 2020 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics (NASDAQ:CBAY) Upgraded at Zacks Investment Research
08:34am, Thursday, 30'th Apr 2020
Zacks Investment Research upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from a hold rating to a buy rating in a research report released on Monday morning, Zacks.com reports. Zacks Investment
CymaBay Therapeutics Inc (NASDAQ:CBAY) Expected to Post Earnings of -$0.29 Per Share
09:52am, Tuesday, 28'th Apr 2020
Equities analysts expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to post earnings of ($0.29) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for CymaBay The
7 Disruptive Biotech Stocks to Buy for 2025
02:56pm, Monday, 27'th Apr 2020
RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.
CymaBay Therapeutics (NASDAQ:CBAY) Downgraded by Zacks Investment Research
11:52am, Monday, 20'th Apr 2020
Zacks Investment Research cut shares of CymaBay Therapeutics (NASDAQ:CBAY) from a buy rating to a hold rating in a research report report published on Thursday, Zacks.com reports. According to Zacks,
Goldman Sachs Group Inc. Raises Stock Holdings in CymaBay Therapeutics Inc (NASDAQ:CBAY)
11:16am, Monday, 20'th Apr 2020
Goldman Sachs Group Inc. grew its stake in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 46.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exch
Renaissance Technologies LLC Buys 384,920 Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY)
08:22am, Monday, 13'th Apr 2020
Renaissance Technologies LLC grew its holdings in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 964.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 424,840 shares o
